Melms, Johannes C. http://orcid.org/0000-0002-5410-6586
Biermann, Jana http://orcid.org/0000-0002-8907-4633
Huang, Huachao
Wang, Yiping
Nair, Ajay http://orcid.org/0000-0003-4521-5614
Tagore, Somnath
Katsyv, Igor
Rendeiro, André F.
Amin, Amit Dipak
Schapiro, Denis
Frangieh, Chris J.
Luoma, Adrienne M.
Filliol, Aveline
Fang, Yinshan
Ravichandran, Hiranmayi
Clausi, Mariano G.
Alba, George A.
Rogava, Meri
Chen, Sean W.
Ho, Patricia http://orcid.org/0000-0002-4622-8188
Montoro, Daniel T.
Kornberg, Adam E.
Han, Arnold S.
Bakhoum, Mathieu F. http://orcid.org/0000-0001-8989-8205
Anandasabapathy, Niroshana
Suárez-Fariñas, Mayte http://orcid.org/0000-0001-8712-3553
Bakhoum, Samuel F.
Bram, Yaron
Borczuk, Alain
Guo, Xinzheng V.
Lefkowitch, Jay H.
Marboe, Charles
Lagana, Stephen M.
Del Portillo, Armando
Tsai, Emily J.
Zorn, Emmanuel http://orcid.org/0000-0001-9985-8389
Markowitz, Glen S.
Schwabe, Robert F.
Schwartz, Robert E. http://orcid.org/0000-0002-5417-5995
Elemento, Olivier
Saqi, Anjali
Hibshoosh, Hanina
Que, Jianwen http://orcid.org/0000-0002-6540-6701
Izar, Benjamin http://orcid.org/0000-0003-2379-6702
Article History
Received: 16 November 2020
Accepted: 19 April 2021
First Online: 29 April 2021
Change Date: 8 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-021-03921-5
Competing interests
: B.I. is a consultant for Merck and Volastra Therapeutics. O.E. is a scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and OneThree Biotech. R.E.S. is a member of the scientific advisory board of Miromatrix Inc. and is a speaker and consultant for Alnylam Inc. D.T.M. is a consultant for LASE Innovation, Inc. S.F.B. owns equity in, receives compensation from, and serves as a consultant for and on the Scientific Advisory Board and Board of Directors of Volastra Therapeutics Inc. The other authors declare no competing interests.
Free to read: This content has been made available to all.